Taken together, these data highlight the hazards of assessing disease activity and therapeutic response solely on measures considered to be more objective of RA disease pathology (such as SJC, CRP and the 2C-DAS28 and MSUS measures) and overlooking broader indicators of disease activity, including PRO. This evidence concerns the gene CRP and rheumatoid arthritis.